Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Allergan

Status and phase: Completed; Phase 4

Conditions: Hypotrichosis

Treatments: Drug: bimatoprost vehicle solution; Drug: bimatoprost ophthalmic solution 0.03%

Study type: Interventional

Funder types: Industry

Identifiers

NCT01448525

GMA-LTS-11-002

Details and patient eligibility

About

The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.

Enrollment: 88 patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have inadequate eyelashes
• Never used prescription eyelash growth products

Exclusion criteria

• No visible eyelashes
• Permanent eyeliner or eyelash implants
• Semi-permanent eyelash tint, dye, or extensions within 3 months
• Over-the-counter eyelash growth products within 6 months
• Any disease, infection or abnormality of the eye or area around the eye
• Eye surgery within 3 months, or the anticipated need for eye surgery during the study
• Unable or unwilling to keep contact lenses out during drug application and for 30 minutes after application

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

88 participants in 2 patient groups, including a placebo group

bimatoprost ophthalmic solution 0.03%

Active Comparator group

Description:

One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.

Treatment:

Drug: bimatoprost ophthalmic solution 0.03%

bimatoprost vehicle solution

Placebo Comparator group

Description:

One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.

Treatment:

Drug: bimatoprost vehicle solution